What’s new at this update
EMA starts evaluation of Pfizer/BioNTech vaccine in adolescents 12 to 15 years
The European Medicines Agency’s human medicines committee will carry out an accelerated assessment of data, including results from a large ongoing clinical study that included adolescents 12 years of age and older, in order to decide whether to recommend an extension to the current indication. The Pfizer/BioNTech vaccine is currently authorized in people 16 years of age and older. A decision is expected in June.
See the Prevention section for more information.
AHA/ASA publish guidance on management of vaccine-induced immune thrombotic thrombocytopenia
The American Heart Association/American Stroke Association have published new guidance on the management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. The guideline recommends treatment with intravenous immune globulin first-line, alongside treatment with an alternative anticoagulant to heparin.
See the Prevention section for more information.
New variants under investigation
Two new SARS-CoV-2 variants, VUI-21APR-02 and VUI-21APR-03, have been designated variants under investigation in the UK. These variants were first identified in India and cases have been reported in the UK. There is currently no evidence that these variants cause more severe disease or render vaccines any less effective.
See the Etiology section for more information.
[Figure caption and citation for the preceding image starts]: Number of COVID-19 cases reported weekly by WHO Region, and global deaths, as of 2 May 2021World Health Organization [Citation ends].
Original source of updateexternal link opens in a new window
Summary
Definition
History and exam
Other diagnostic factors
- fatigue
- myalgia or arthralgia
- sputum production/expectoration
- chest tightness
- gastrointestinal symptoms
- sore throat
- headache
- dizziness
- neurologic symptoms
- ocular symptoms
- rhinorrhea/nasal congestion
- audio-vestibular symptoms
- chest pain
- cutaneous symptoms
- lower urinary tract symptoms
- hemoptysis
- bronchial breath sounds
- tachypnea
- tachycardia
- cyanosis
- crackles/rales on auscultation
Risk factors
- contact with probable or confirmed case
- residence/work/travel in location with high risk of transmission
- older age
- male sex
- ethnicity
- residence in a long-term care facility
- presence of comorbidities
- obesity
- cardiovascular disease
- diabetes
- chronic respiratory disease
- chronic kidney disease
- pregnancy
- smoking
- malignancy
- cerebrovascular disease
- solid organ or blood stem cell transplant
- Down syndrome
- hemoglobin disorders
- hypertension
- dementia
- immunosuppression
- HIV infection
- substance use disorders
- children with certain underlying conditions
- chronic liver disease
- vitamin D deficiency
- proton-pump inhibitor use
- autoimmune disease
- Parkinson disease
- physical inactivity
- dyslipidemia
- surgery
- blood groups A and B
- gut dysbiosis
- environmental factors
Diagnostic investigations
1st investigations to order
- real-time reverse transcription polymerase chain reaction (RT-PCR)
- pulse oximetry
- ABG
- CBC
- comprehensive metabolic panel
- blood glucose level
- coagulation screen
- cardiac biomarkers
- serum C-reactive protein
- serum erythrocyte sedimentation rate
- serum lactate dehydrogenase
- serum interleukin-6 level
- serum procalcitonin
- serum ferritin level
- serum amyloid A level
- serum creatine kinase and myoglobin
- blood and sputum cultures
- chest x-ray
Investigations to consider
- computed tomography (CT) chest
- serology
- antigen test
Emerging tests
- reverse transcription loop-mediated isothermal amplification (RT-LAMP)
- lung ultrasound
- calprotectin
Treatment algorithm
Contributors
Authors
Consultant and Emeritus Professor of Tropical and Infectious Diseases
Royal Liverpool University Hospital and Liverpool School of Tropical Medicine
Liverpool
UK
Disclosures
NJB is partially supported by the National Institute of Health Research Health Protection Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine. He is affiliated with Liverpool School of Tropical Medicine. The views expressed are those of the author and not necessarily those of the NHS, the NIHR, the Department of Health, or PHE.
Senior Clinical Lecturer and Defence Consultant in Infectious Diseases
Royal Liverpool University Hospital and Liverpool School of Tropical Medicine
Liverpool
UK
Disclosures
TEF is a consultant/expert panel member to the World Health Organization, and is funded by the UK Surgeon General, the NHS, and Liverpool School of Tropical Medicine. TEF is partially supported by the National Institute of Health Research Health Protection Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine. He is affiliated with Liverpool School of Tropical Medicine. He has received research grants from the Wellcome Trust, Medical Research Council, and the UK Public Health Rapid Support Team (UK-PHRST). The views expressed are those of the author and not necessarily those of the NHS, the NIHR, the Department of Health, or PHE.
H. Barrie Fairley Professor of Critical Care
University Health Network and Interdepartmental Division of Critical Care Medicine
Director
Clinical Epidemiology and Health Care Research
Institute of Health Policy, Management and Evaluation
Dalla Lana School of Public Health
University of Toronto
Chief
Tory Trauma Program
Sunnybrook Hospital
Toronto
Canada
Disclosures
RF declares that he has no competing interests.
Peer reviewers
Professor
Division of Infectious Diseases and International Health
University of Virginia
Charlottesville
VA
Disclosures
WAP declares that he has no competing interests.
Attending Physician
The Fifth Medical Center of PLA General Hospital
Clinical Division and Research Center of Infectious Disease
Beijing
China
Disclosures
XZ declares that he has no competing interests.
Associate Professor in Medicine
Department of Clinical Microbiology and Infectious Diseases
Hadassah Hebrew University Medical Center
Jerusalem
Israel
Disclosures
RNP has received research grants from US-Israel Binational Science Foundation, Hebrew University, Rosetrees Trust, and SpeeDx. He is chair of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC). RNP is a consultant for and has stocks in eDAS Healthcare. He is also chairperson of the Israeli Society for Infectious Diseases guidelines committee.
Use of this content is subject to our disclaimer